Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Recently Adopted and Issued Accounting Guidance - Consolidated Balance Sheets (Details)

v3.10.0.1
Recently Adopted and Issued Accounting Guidance - Consolidated Balance Sheets (Details) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]    
Other current assets $ 6,161 $ 5,153
Other assets 1,302 891
Total Assets   344,454
Current pharma contract liability 2,155 1,406
Long-term pharma contract liability 648 283
Deferred income tax liability, net 6,827 6,688
Stockholders' Equity 164,209 171,962
Total Liabilities and Stockholders' Equity $ 345,783 344,454
As Reported    
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]    
Other current assets   4,241
Other assets   689
Total Assets   343,340
Current pharma contract liability   0
Long-term pharma contract liability   0
Deferred income tax liability, net   6,307
Stockholders' Equity   172,918
Total Liabilities and Stockholders' Equity   343,340
Impact of Adoption | Accounting Standards Update 2014-09    
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]    
Other current assets   912
Other assets   202
Total Assets   1,114
Current pharma contract liability   1,406
Long-term pharma contract liability   283
Deferred income tax liability, net   381
Stockholders' Equity   (956)
Total Liabilities and Stockholders' Equity   $ 1,114